Not an antibody company: Elasmogen banks £8M to advance VNAR platform May 25, 2022 By Nuala Moran Elasmogen Ltd. has secured a “transformational” £8 million (US$10 million) in new funding with which to move its shark-based, antibody-like constructs toward the clinic.Read More
Lysine reactive salicylaldehyde probe exhibits kinase selectivity with sustained occupancy May 25, 2022
RSS
